melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofiling
Melior Discovery
home
Therapeutic Areas
Safety Assessment
 

 

theraTRACE

 

theraTRACE

Melior Pharmaceuticals

melior melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofiling

Melior Discovery gastrointestinal

Gastrointestinal Transit Assay
Drug-related bowel function side effects can cause a great deal of discomfort and pain.  These side effects can include constipation, abdominal constriction or diarrhea.  This model is designed to identify compounds that produce effects on bowel function and cause inhibition on gut transit.  The model evaluates morphine's effects on inhibiting gastrointestinal function. 

                           GI Transit Abdominal pain constipation

 

Percent transit of choarcoal bolus in the intestines.  Mice were treated with either vehicle or Morphine 30 minutes prior to charcoal administration.  Twenty minutes later, intestines were removed from the mice and uncoiled to determine the distance traveled by the choarcoal bolus through the GI tract.  The Morphine group displayed a reduction in percent transit of the bolus compared to the vehicle treated mice. Data are mean ± SEM; ****p<0.001 compared to vehicle.

 

If you are interested in learning more about the Gastrointestinal Transit Assay, please contact models@meliordiscovery.com to start the conversation.